CTLA4 and myocarditis: The non-susceptibility of anti-CTLA-4 to pericarditis and myocarditis was due to the difference of disease-specific effects (Salem et al., 2018; Ma et al., 2021) and mechanism (Grabie et al., 2019), respectively.